CN104364391A - 用于诊断和治疗癌症的涉及ros1融合的方法和组合物 - Google Patents

用于诊断和治疗癌症的涉及ros1融合的方法和组合物 Download PDF

Info

Publication number
CN104364391A
CN104364391A CN201380013401.4A CN201380013401A CN104364391A CN 104364391 A CN104364391 A CN 104364391A CN 201380013401 A CN201380013401 A CN 201380013401A CN 104364391 A CN104364391 A CN 104364391A
Authority
CN
China
Prior art keywords
ros1
primer
cancer
pcr
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380013401.4A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·豪特
约翰·汉德舒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Genetics Inc
Original Assignee
Insight Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Genetics Inc filed Critical Insight Genetics Inc
Publication of CN104364391A publication Critical patent/CN104364391A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380013401.4A 2012-02-08 2013-02-08 用于诊断和治疗癌症的涉及ros1融合的方法和组合物 Pending CN104364391A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596720P 2012-02-08 2012-02-08
US61/596,720 2012-02-08
PCT/US2013/025345 WO2013119950A2 (fr) 2012-02-08 2013-02-08 Procédés et compositions concernant des fusions de ros1 pour diagnostiquer et traiter le cancer

Publications (1)

Publication Number Publication Date
CN104364391A true CN104364391A (zh) 2015-02-18

Family

ID=48948165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013401.4A Pending CN104364391A (zh) 2012-02-08 2013-02-08 用于诊断和治疗癌症的涉及ros1融合的方法和组合物

Country Status (5)

Country Link
EP (1) EP2812451A4 (fr)
JP (1) JP2015508644A (fr)
CN (1) CN104364391A (fr)
AU (1) AU2013216904A1 (fr)
WO (1) WO2013119950A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138230A (zh) * 2015-07-21 2018-06-08 夸登特健康公司 用于捕获融合基因的锁核酸

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811090T3 (es) 2013-09-10 2021-03-10 Univ Texas Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc)
US10231965B2 (en) * 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
WO2015148494A1 (fr) * 2014-03-25 2015-10-01 Quest Diagnostics Investments Incorporated Détection de fusions de gènes par expression différentielle intragénique (ide) à l'aide de seuils de cycle moyen
US10082496B2 (en) * 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ，インコーポレイテッド 神経芽細胞腫の治療のための併用
CN104830989A (zh) * 2015-05-25 2015-08-12 上海允英医疗科技有限公司 一种用于ros1与多种基因发生融合突变的检测试剂盒
WO2017106492A1 (fr) 2015-12-18 2017-06-22 Ignyta, Inc. Combinaisons pour le traitement du cancer
BR112020000793A2 (pt) 2017-07-19 2020-07-14 Ignyta, Inc. composições farmacêuticas e formas de dosagem
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN113473990A (zh) * 2018-10-08 2021-10-01 锐新医药公司 用于治疗癌症的shp2抑制剂组合物
WO2024072805A1 (fr) * 2022-09-26 2024-04-04 Lau, Johnson Yiu-Nam Compositions, systèmes et procédés pour la détection du cancer de l'ovaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240434A1 (en) * 2003-03-07 2006-10-26 Jean Gabert Standardized and optimized real-time quantitative reverse transcriptase polymerase chain reaction method for detection of mrd in leukemia
CN101528921A (zh) * 2006-01-20 2009-09-09 细胞信号技术有限公司 人非小细胞肺癌中的易位和突变的ros激酶
WO2010132888A2 (fr) * 2009-05-15 2010-11-18 Insight Genetics, Inc. Méthodes et compositions associés à des fusions de la kinase alk pour diagnostiquer et traiter le cancer
US20110287445A1 (en) * 2009-02-12 2011-11-24 Cell Signaling Technology, Inc. Mutant ROS Expression In Human Cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143918A1 (en) * 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20130288240A1 (en) * 2010-05-21 2013-10-31 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US9109259B2 (en) * 2010-06-22 2015-08-18 Japanese Foundation For Cancer Research Detection method for novel ROS1 fusions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240434A1 (en) * 2003-03-07 2006-10-26 Jean Gabert Standardized and optimized real-time quantitative reverse transcriptase polymerase chain reaction method for detection of mrd in leukemia
CN101528921A (zh) * 2006-01-20 2009-09-09 细胞信号技术有限公司 人非小细胞肺癌中的易位和突变的ros激酶
US20110287445A1 (en) * 2009-02-12 2011-11-24 Cell Signaling Technology, Inc. Mutant ROS Expression In Human Cancer
WO2010132888A2 (fr) * 2009-05-15 2010-11-18 Insight Genetics, Inc. Méthodes et compositions associés à des fusions de la kinase alk pour diagnostiquer et traiter le cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138230A (zh) * 2015-07-21 2018-06-08 夸登特健康公司 用于捕获融合基因的锁核酸
CN108138230B (zh) * 2015-07-21 2023-03-10 夸登特健康公司 用于捕获融合基因的锁核酸

Also Published As

Publication number Publication date
WO2013119950A3 (fr) 2014-11-13
JP2015508644A (ja) 2015-03-23
EP2812451A4 (fr) 2016-01-06
WO2013119950A2 (fr) 2013-08-15
EP2812451A2 (fr) 2014-12-17
AU2013216904A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
CN104364391A (zh) 用于诊断和治疗癌症的涉及ros1融合的方法和组合物
JP6397833B2 (ja) 癌を診断および治療するためのａｌｋの融合に関する方法および組成物
CN102388151A (zh) 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物
EP1966395B1 (fr) Témoins pour essais d acides nucléiques
EP3246332B1 (fr) Oligonucléotides et procédés et détection de mutations de pik3ca
NZ566387A (en) Method to predict or monitor the response of a patient to an ErbB receptor drug by screening for mutations in an ErbB receptor
JP2019519540A (ja) 肺癌患者におけるａｌｋ阻害薬療法に対する応答を予測する未分化リンパ腫キナーゼにおける新規な変異
CA2886397A1 (fr) Procedes et compositions associees au sequencage de nouvelle generation et utilisables dans le cadre d'analyses genetiques portant sur les cancers lies a alk
JP6153758B2 (ja) 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット
US9428812B2 (en) Kit comprising primers for amplifying ALK kinase domain nucleic acids
US20150232940A1 (en) Methods and compositions relating to diagnosing and treating receptor tyrosine kinase related cancers
JP6205216B2 (ja) 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
KR20100037639A (ko) Ｅｇｆｒ 억제제를 이용한 치료에 대한 예측 마커
US20150240301A1 (en) Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
WO2014026133A1 (fr) Méthodes et compositions associées à alk pour le diagnostic et le traitement de cancers du sein inflammatoires et d'autres cancers humains
NICKOLS et al. Patent 2762108 Summary
JP2002058483A (ja) グルタチオンｓ−転移酵素の測定方法、そのためのプローブ及びキット

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150218